204 related articles for article (PubMed ID: 34659549)
1. CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis.
Ye W; Luo C; Li C; Liu Z; Liu F
J Cancer; 2021; 12(21):6588-6599. PubMed ID: 34659549
[No Abstract] [Full Text] [Related]
2. CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis.
Ye W; Luo C; Liu F; Liu Z; Chen F
Front Oncol; 2021; 11():634617. PubMed ID: 33680972
[TBL] [Abstract][Full Text] [Related]
3. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
7. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
8. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
9. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
10. Pan-Cancer Analysis of the Prognostic and Immunological Role of SMG5: A Biomarker for Cancers.
Yang L; Wei J; Ma X; Cheng R; Zhang H; Jin T
Oncology; 2024; 102(2):168-182. PubMed ID: 37699361
[TBL] [Abstract][Full Text] [Related]
11. A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy.
Li H; Zhou K; Wang K; Cao H; Wu W; Wang Z; Dai Z; Chen S; Peng Y; Xiao G; Luo P; Zhang J; Liu Z; Cheng Q; Zhang H
Front Immunol; 2022; 13():1040289. PubMed ID: 36660546
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
14. Clusterin Is a Prognostic Biomarker of Lower-Grade Gliomas and Is Associated with Immune Cell Infiltration.
Ren X; Chang C; Qi T; Yang P; Wang Y; Zhou X; Guan F; Li X
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686218
[TBL] [Abstract][Full Text] [Related]
15. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.
Zhu H; Hu X; Gu L; Jian Z; Li L; Hu S; Qiu S; Xiong X
Front Genet; 2021; 12():759953. PubMed ID: 34721547
[TBL] [Abstract][Full Text] [Related]
16.
Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and immunological role of cathepsin S gene in pan‑cancer.
Liang S; Dang B; Chen S; Mi H
Oncol Lett; 2024 Jan; 27(1):41. PubMed ID: 38108072
[TBL] [Abstract][Full Text] [Related]
19. CCDC137 Is a Prognostic Biomarker and Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Analysis.
Guo L; Li B; Lu Z; Liang H; Yang H; Chen Y; Zhu S; Zeng M; Wei Y; Liu T; Jiang T; Xuan M; Tang H
Front Mol Biosci; 2021; 8():674863. PubMed ID: 34055889
[TBL] [Abstract][Full Text] [Related]
20. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
[Next] [New Search]
